Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT05386550 |
| Consolidated Lead Sponsor | EMD Serono / Merck KGaA |
| Therapeutic Condition Cohort | Oncology and Hematology |
| Clinical Trial Phase | Phase III |
| Overall Recruitment Status | TERMINATED |
| Registered Enrollment | 166 participants (ACTUAL) |
| Registered Start Date | 2022-10-06 |
| WhyStopped Classification | Unspecified |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| Dana-Farber Cancer Institute | Boston, MA | Open Hospital Dossier -> |
| Barbara Ann Karmanos Cancer Institute | Detroit, MI | Open Hospital Dossier -> |
| NYU Langone Health and Perlmutter Cancer Center | New York, NY | Open Hospital Dossier -> |
Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.